Comparison study of patient demographics and patient-related risk factors for peri-prosthetic joint infections following primary total shoulder arthroplasty

BackgroundWhile studies have demonstrated favorable outcomes in utilization of primary total shoulder arthroplasty (TSA) for the treatment of glenohumeral osteoarthritis (OA), adverse events such as infections can still occur. Periprosthetic joint infections (PJIs) are associated with worse outcomes and patient morbidity. The purpose of this study was to: (1) compare patient demographics amongst TSA patients with and without PJIs following primary TSA; and (2) identify patient-related risk factors for PJIs following primary TSA.MethodsPatients undergoing primary TSA for the treatment of glenohumeral OA were identified using the Mariner administrative claims database by CPT code 23,472. Laterality modifiers were utilized to ensure PJIs were developing in the correct laterality as those patients undergoing primary TSA. Inclusion for the study group consisted of patients who developed PJIs within 2-years after the index procedure, whereas patients who did not develop PJIs served as the comparison cohort. Primary outcomes analyzed included patient demographics and patient-related risk factors for PJIs following primary TSA. A stepwise backwards elimination multivariate binomial logistic regression analyses was performed to determine the odds (OR) of PJIs in patients undergoing primary TSA. A P value less than .05 was considered statistically significant.ResultsThe query yielded 15,396 patients who underwent primary TSA for glenohumeral OA, of which 191 patients developed PJIs and 15,205 did not develop PJIs. The study found statistically significant differences amongst patients who did and did not develop PJIs following primary TSA with respect to age, sex, and presence of comorbid conditions. Risk factors associated with developing PJIs following primary TSA included: pathologic weight loss (OR: 2.06, P < .0001), obesity (OR: 1.56, P = .0001), male sex (OR: 1.52, P = .007), and peripheral vascular disease (OR: 1.46, P = .022).ConclusionAs the number of primary TSAs for the treatment of glenohumeral OA increase worldwide, identifying modifiable risk-factors to reduce the incidence of infection is critical. The study found various modifiable and non-modifiable risk factors associated with developing PJIs following primary TSA. This study is valuable to orthopedists in order to identify and risk-stratify patients with regard to PJI in the setting of primary TSA for OA.Level of EvidenceLevel III; Case-Control Study     

生慧汤对APP/PS1雄性AD小鼠海马内APP代谢产物的昼夜变化影响＊

目的研究生慧汤对APP/PS1（β-amyloid precursor protein/presenilin 1246E）小鼠海马内β淀粉样前体蛋白（Amyloid precursor protein，APP）代谢产物昼夜表达的影响。方法 将56只雄性APP/PS1双转基因痴呆模型小鼠随机分为4组，分别为：痴呆模型组、褪黑素治疗组（0.78 mg·kg^-1·d^-1）、生慧汤高剂量组（27.0 g·kg^-1·d^-1）、生慧汤低剂量组（13.5 g·kg^-1·d^-1），每组14只；对照组为14只雄性C57BL/6J小鼠，连续给药30天。采用Morris水迷宫检测小鼠学习记忆能力，采用酶联免疫吸附检测（ELISA）检测不同时间段取出的海马组织sAPPα含量。对海马β淀粉样蛋白_1-40、β淀粉样蛋白_1-42表达进行免疫印迹分析。免疫组化（IHC）检测海马CA1区Aβ_1-40蛋白的表达。结果 Morris水迷宫结果表明，与对照组相比，模型组上平台潜伏期明显延长、穿越平台次数明显减少（P<0.01）；与模型组相比，生慧汤不同剂量组上平台潜伏期明显缩短（P<0.01、P<0.05），穿越平台次数明显增加（P<0.05）。ELISA结果表明，与对照组相比，模型组的sAPPα总量、各时间段（12：00、24：00）sAPPα含量明显减少（P<0.01）；与模型组相比，生慧汤不同剂量组sAPPα总量明显增多（P<0.01、P<0.05），生慧汤高剂量组仅能增加12：00 sAPPα含量（P<0.01），生慧汤低剂量组仅能增加24：00 sAPPα含量（P<0.05）。对照组sAPPα含量具有明显昼夜差异（P<0.01）。模型组sAPPα含量的昼夜差异性消失（P>0.05）。生慧汤高剂量组sAPPα含量具有昼夜差异（P<0.01），生慧汤低剂量组sAPPα含量不具有昼夜差异（P>0.05）。Western blot结果显示，与对照组相比，模型组Aβ_1-40、Aβ_1-42蛋白表达明显增加（P<0.01）；与模型组相比，生慧汤高剂量组Aβ_1-40、Aβ_1-42蛋白表达减少（P<0.05、P<0.01）；生慧汤低剂量组仅能减少Aβ_1-40蛋白的表达（P<0.05），对Aβ_1-42蛋白表达无影响（P>0.05）。免疫组化结果表明，与对照组相比，模型组Aβ_1-40表达明显增加（P<0.01）；与模型组相比，生慧汤不同剂量组Aβ_1-40表达不同程度减少（P<0.01、P<0.05）。结论 生慧汤能够改善5月龄APP/PS1阿尔茨海默病模型小鼠的学习记忆障碍，其机制可能与恢复海马内APP代谢产物sAPPα的昼夜节律性表达、从而减少Aβ的沉积有关。     

手术室髋关节置换术男性患者导尿方式选择

目的探讨髋关节置换术男性患者在腰麻后行侧卧位留置尿管的临床效果。 方法选取茂名市人民医院麻醉手术科100例采取椎管内麻醉实施髋关节置换术的男性患者，排除尿道畸形和前列腺增生者。按照住院号尾数单双号分为观察组和对照组，每组各50例。观察组在麻醉诱导成功后行侧卧位行导尿术，对照组在麻醉成功后改平卧位留置尿管，再调整为手术体位。采用卡方检验和t检验分析及比较两组间的尿道损伤、一次导尿成功率、手术准备时间和单侧麻醉效果。 结果观察组和对照组分别有3例(6%)和4例(8%)尿道损伤，差异无统计学意义(P>0.05)；两组的一次导尿成功率比较，差异也无统计学意义(P>0.05)；手术准备时间(t＝20.802)和单侧麻醉效果(χ²＝59.278)相比观察组均优于对照组，且差异具有统计学意义(P<0.01)。 结论髋关节置换术男性患者麻醉后采取侧卧位导尿，有利于缩短手术准备时间和提升单侧麻醉效果，且不增加尿道损伤。     

Patient Perspectives on Benign Prostatic Hyperplasia Surgery: A Focus on Sexual Health

BackgroundIn the last decade, many novel minimally invasive surgical techniques within benign prostatic hyperplasia (BPH) surgery were developed to reduce postoperative complications that often discourage patients from pursuing BPH surgery.AimTo assess perspective of future and past international BPH surgery patients regarding their postoperative complications, namely erectile and ejaculatory function.MethodsA survey was distributed randomly to 2 groups of BPH patients: one with 149 patients having undergone surgery in the last 2 years (group A), and the other cohort of 151 men seriously considering BPH surgery in the next year (group B). This survey consisted of 20 questions that assessed patients' motivating factors for undergoing elective BPH surgery and their perspectives regarding the potential postoperative complications attributed to BPH surgery.OutcomesThe perspective of future and past international BPH surgical patients towards the preservation of their erectile and ejaculatory functions was assessed with the help of a survey.ResultsResults indicated that in general BPH surgery patients considered the maintenance of erectile (95%, n = 284) and ejaculatory function (92%, n = 276) to be important preoperative considerations, regardless of their age. Patients aged 50–59 years were most concerned with the permanent impact on sexual function and patients aged >60 years were most concerned with urinary incontinence. In patients aged >70 years, 66% (n = 43) and 62% (n = 40) of the respondents indicated that maintaining erectile and ejaculatory function was important, respectively.Clinical ImplicationsPatient-centered care needs to be implemented in order to address the importance that past and future BPH surgery patients hold toward the maintenance of their postoperative sexual function.Strengths & LimitationsIn the group of patients having previously undergone BPH surgery, the possibility of recall bias should be taken into account when interpreting the study's findings. However, maintaining sexual function was also important for the group of patients seriously considering surgery in the next year suggesting that these considerations are not solely due to recall bias. Additionally, the results were limited by the small sample size of participants in groups A (n = 149) and B (n = 151).ConclusionIt was found that past and future BPH surgery patients attribute a significant importance toward the maintenance of their sexual function. Although novel approaches with better sexual outcomes such as Rezum and UroLift for prostates <80 mL, and Aquablation for any size prostate are available, more research is needed to investigate their long-term effects on sexual function before they can be recommended to patients.Bouhadana D, Nguyen D-D, Zorn KC, et al. Patient Perspectives on Benign Prostatic Hyperplasia Surgery: A Focus on Sexual Health. J Sex Med 2020;17:2108–2112.     

补肾阳中药治疗促性腺激素缺乏型男性不育的网络分子机制初探

目的初探补肾阳中药治疗促性腺激素缺乏型男性不育的潜在分子机制。方法结合生物信息学方法建立补肾阳中药的成分库、表征美国食品药品监督管理局(Food and Drug Administration,FDA)批准用于治疗促性腺激素缺乏男性不育的药物靶标库;再应用通路分析软件(ingenuity pathway analysis,IPA)将成分库投影靶标库,筛选出可作用于靶标及通路的成分,预测分子成分功能,构建“成分-靶标”分子网络。结果分别建立了补肾阳中药成分库(242个化合物)与FDA批准药物靶标库(565个靶标),成分库与靶标库投影后发现补肾阳中药成分库中的30个化学成分可直接激活或抑制药物靶标库中的60个靶标,参与缺氧诱导因子1-α(hypoxia-inducible factor 1-alpha,HIF1α)信号途径,血小板反应蛋白1(thrombospondin 1,TSP1)抑制血管生成途径,芳基烃受体信号途径,孕烷X受体(pregnane X receptor,PXR)/类视黄醇X受体(retinoid X receptor,RXR)激活等18条通路的直接调控。结论本研究构建了补肾阳中药治疗促性腺激素缺乏型男性不育的“成分-靶标”分子网络,分析其治疗效应机制,为补肾阳中药治疗促性腺激素缺乏型男性不育奠定理论基础和实验依据,具有一定的科学意义。     

Developmental Exposure to Tetrabromobisphenol A Has Minimal Impact on Male Rat Reproductive Health

The flame retardant and plasticizer, tetrabromobisphenol-A (TBBPA) has rapidly become a common component in the manufacture of circuit boards and plastics worldwide. It is also an analog of bisphenol A (BPA), an endocrine disrupting chemical identified by the Endocrine Society. As such, TBBPA needs to be investigated for similar potential human health risks. Using rats as a model, we exposed pregnant dams and their progeny to 0, 0.1, 25, or 250 mg TBBPA/kg of body weight until the offspring reached adulthood and assessed the first generation of males for any reproductive tract abnormalities. We found no differences in the morphology of testes, sperm, prostates, or secondary sex organs from post-natal day 21 through one-year of age. A delay in the time to preputial separation was found with the 250 mg/kg treatment. Also, minor differences of sperm count at one-year old with the 25 mg/kg treatment and expression levels of two steroidogenic pathway enzymes at either post-natal day 90 or one-year old in the 250 mg/kg treatment group were detected, but spermatogenesis was not disrupted. While these results may lead to the supposition that TBBPA is less harmful than its parent compound BPA, more studies need to be conducted to assess long-term exposure effects.